Robert L. Ferris
University of Pittsburgh
H-index: 110
North America-United States
Top articles of Robert L. Ferris
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design | Robert L Ferris Hisham Mehanna Jonathan D Schoenfeld Makoto Tahara Sue S Yom | 2023/12 | |
XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-risk, Cisplatin-ineligible Patients with Resected, Locally Advanced Squamous Cell Carcinoma of the … | Robert L Ferris Hisham Mohamed Mehanna Jonathan Daniel Schoenfeld Makoto Tahara Sue S Yom | 2023/6/1 | |
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory … | International Journal of Radiation Oncology, Biology, Physics | Robert L Ferris Pedro Torres-Saavedra Ravindra Uppaluri Min Yao Josephine Chen | 2024/4/1 |
Th2 Cells Are Associated with Tumor Recurrence Following Radiation | Cancers | Mohamed K Abdelhakiem Riyue Bao Phillip M Pifer David Molkentine Jessica Molkentine | 2024/4/20 |
A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed … | International Journal of Radiation Oncology, Biology, Physics | Dan P Zandberg Jie Chen Curtis Tatsuoka Daniel P Normolle James Ohr | 2024/4/1 |
Over 132 Years Ago, the Inaugural Immunotherapy Treated Its First Head and Neck Cancer Patient | Otolaryngology–Head and Neck Surgery | Joey Martin Stéphane Hans Robert L Ferris Robin Baudouin | 2024/4/8 |
All-trans retinoic acid induces durable tumor immunity in IDH-mutant gliomas by rescuing transcriptional repression of the CRBP1-retinoic acid axis | bioRxiv | Aparna Rao Xiaoran Zhang Anthony Cillo Jonathan H Sussman Poorva Sandlesh | 2024 |
Randomized Phase 2 Trial of Stereotactic Body Radiation Therapy (SBRT) and Concurrent and Adjuvant Cetuximab vs Cetuximab and Docetaxel in Recurrent, Previously Irradiated … | International Journal of Radiation Oncology, Biology, Physics | CT Wilke RL Ferris J Ohr DP Zandberg Z Rahman | 2024/4/1 |
Adjusted RECIST Criteria for Assessing Time to Recurrence in Patients with Fully Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) | International Journal of Radiation Oncology, Biology, Physics | S Peter Eggleton M O'Neal Robert Ford Andreas Schroeder Marcis Bajars | 2024/4/1 |
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors | Journal for immunotherapy of cancer | Nikhil I Khushalani Patrick A Ott Robert L Ferris Tina Cascone Dirk Schadendorf | 2024 |
Treatment package time< 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features | Oral Oncology | Manasa Melachuri Chareeni Kurukulasuriya Purva Rumde Terral Patel Daniel Awad | 2024/4/1 |
Outcomes in Patients with Oral Cavity Squamous Cell Carcinomas with Respect to Initiation of Chemotherapy and Adjuvant IMRT Timing | International Journal of Radiation Oncology, Biology, Physics | KR Cargill JAA Vargo U Iheagwara S Kim MW Kubik | 2024/4/1 |
Genomic and transcriptomic analysis of cutaneous squamous cell carcinoma arising in immunocompetent and immunosuppressed patients | Oral Oncology | Kristin P Bibee Aditi Kulkarni Sanghoon Lee Johan Ho Hatice Ulku Osmanbeyoglu | 2024/1/1 |
Oropharyngeal carcinoma with a special focus on HPV-related squamous cell carcinoma | Robert L Ferris William Westra | 2023/1/24 | |
Safety of nivolumab added to chemoradiation therapy platforms for intermediate and high-risk locoregionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504 | International Journal of Radiation Oncology* Biology* Physics | Maura L Gillison Robert L Ferris Jonathan Harris A Dimitrios Colevas Loren K Mell | 2023/3/15 |
CD39+ and Tim3+ T reg are potential effector cells in the peripheral blood and tumor microenvironment of head and neck squamous cell carcinoma patients | Laryngo-Rhino-Otologie | Cornelius Kürten Aditi Kulkarni Lazar Vujanovic AnthonyR Cillo Tullia Bruno | 2023/5 |
Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate … | Clinical Cancer Research | Nizar M Tannir Sabina Signoretti Toni K Choueiri David F McDermott Robert J Motzer | 2021/1/1 |
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC). | Robert L Ferris William E Gooding Simion I Chiosea Umamaheswar Duvvuri Seungwon Kim | 2023/6/1 | |
856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and … | Annals of Oncology | DP Zandberg DA Clump BR Isett R Bao H Wang | 2023/10/1 |
Longitudinal analysis of caregiver burden in head and neck cancer | JAMA Otolaryngology–Head & Neck Surgery | Lauren D Kudrick Khalil Baddour Richard Wu Mark Fadel Vusala Snyder | 2023/8/1 |
